Ser304

Site Information
KAEAKEEsEEsDEDM SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 454133

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 )
Disease tissue studied:	anthrax infection ( 15 ) , leukemia ( 10 ) , acute myelogenous leukemia ( 10 ) , lymphoma ( 41 ) , B cell lymphoma ( 41 ) , melanoma skin cancer ( 34 )
Relevant cell line - cell type - tissue:	'3T3-L1, differentiated' (adipocyte) ( 5 ) , 'brain, cerebellum' ( 36 ) , 'brain, cerebral cortex' ( 36 ) , 'brain, embryonic' ( 23 , 24 , 29 , 32 ) , 'brain, hippocampus, dentate gyrus' ( 36 ) , 'brain, midbrain' ( 36 ) , 'fat, brown' ( 16 ) , 32Dcl3 (myeloid) [FLT3 (mouse), transfection, chimera with human FLT3-ITD mutant (corresponding to wild type P36888 ( 20 ) , 32Dcl3 (myeloid) ( 20 ) , BaF3 ('B lymphocyte, precursor') [JAK3 (human), transfection] ( 1 ) , blood ( 10 ) , brain ( 11 , 16 , 18 , 22 , 30 , 31 , 40 ) , C2C12 (myoblast) ( 21 ) , heart ( 6 , 16 , 27 , 28 ) , Hepa 1-6 (epithelial) ( 35 ) , kidney ( 16 ) , liver ( 4 , 9 , 16 , 25 , 26 , 38 , 39 ) , liver [leptin (mouse), homozygous knockout] ( 9 ) , lung ( 16 ) , macrophage-bone marrow ( 17 ) , macrophage-bone marrow [DUSP1 (mouse), homozygous knockout] ( 17 ) , macrophage-peritoneum ( 8 ) , macrophage-peritoneum [MPRIP (mouse), homozygous knockout] ( 8 ) , MC3T3-E1 (preosteoblast) ( 2 ) , MEF (fibroblast) [p53 (mouse), homozygous knockout] ( 12 ) , MEF (fibroblast) [Raptor (mouse), knockdown] ( 7 ) , MEF (fibroblast) [RICTOR (mouse), knockdown] ( 7 ) , MEF (fibroblast) [TSC2 (mouse), homozygous knockout] ( 13 ) , MEF (fibroblast) ( 7 , 13 ) , mpkCCD (renal) ( 19 ) , P19 (testicular) ( 37 ) , pancreas ( 16 ) , RAW 264.7 (macrophage) ( 3 ) , RAW 267.4 (macrophage) ( 33 ) , skin [mGluR1 (mouse), transgenic, TG mutant mice] ( 34 ) , spleen ( 15 , 16 ) , T lymphocyte-spleen ( 14 ) , testis ( 16 ) , WEHI-231 (B lymphocyte) ( 41 )

Upstream Regulation
Treatments:	BMP2 ( 21 ) , insulin ( 5 ) , LY294002 ( 5 ) , retinoic_acid ( 37 )

References
1	Degryse S, et al. (2017) Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia 32 28852199 Curated Info
2	Williams GR, et al. (2016) Exploring G protein-coupled receptor signaling networks using SILAC-based phosphoproteomics. Methods 92, 36-50 26160508 Curated Info
3	Pinto SM, et al. (2015) Quantitative phosphoproteomic analysis of IL-33-mediated signaling. Proteomics 15, 532-44 25367039 Curated Info
4	Wilson-Grady JT, Haas W, Gygi SP (2013) Quantitative comparison of the fasted and re-fed mouse liver phosphoproteomes using lower pH reductive dimethylation. Methods 61, 277-86 23567750 Curated Info
5	Humphrey SJ, et al. (2013) Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2. Cell Metab 17, 1009-20 23684622 Curated Info
6	Lundby A, et al. (2013) In vivo phosphoproteomics analysis reveals the cardiac targets of β-adrenergic receptor signaling. Sci Signal 6, rs11 23737553 Curated Info
7	Robitaille AM, et al. (2013) Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science 339, 1320-3 23429704 Curated Info
8	Wu X, et al. (2012) Investigation of receptor interacting protein (RIP3)-dependent protein phosphorylation by quantitative phosphoproteomics. Mol Cell Proteomics 11, 1640-51 22942356 Curated Info
9	Grimsrud PA, et al. (2012) A quantitative map of the liver mitochondrial phosphoproteome reveals posttranslational control of ketogenesis. Cell Metab 16, 672-83 23140645 Curated Info
10	Trost M, et al. (2012) Posttranslational regulation of self-renewal capacity: insights from proteome and phosphoproteome analyses of stem cell leukemia. Blood 120, e17-27 22802335 Curated Info
11	Goswami T, et al. (2012) Comparative phosphoproteomic analysis of neonatal and adult murine brain. Proteomics 12, 2185-9 22807455 Curated Info
12	Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22 21659604 Curated Info
13	Yu Y, et al. (2011) Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332, 1322-6 21659605 Curated Info
14	Navarro MN, et al. (2011) Phosphoproteomic analysis reveals an intrinsic pathway for the regulation of histone deacetylase 7 that controls the function of cytotoxic T lymphocytes. Nat Immunol 12, 352-61 21399638 Curated Info
15	Manes NP, et al. (2011) Discovery of mouse spleen signaling responses to anthrax using label-free quantitative phosphoproteomics via mass spectrometry. Mol Cell Proteomics 10, M110.000927 21189417 Curated Info
16	Huttlin EL, et al. (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174-89 21183079 Curated Info
17	Weintz G, et al. (2010) The phosphoproteome of toll-like receptor-activated macrophages. Mol Syst Biol 6, 371 20531401 Curated Info
18	Wiśniewski JR, et al. (2010) Brain phosphoproteome obtained by a FASP-based method reveals plasma membrane protein topology. J Proteome Res 9, 3280-9 20415495 Curated Info
19	Rinschen MM, et al. (2010) Quantitative phosphoproteomic analysis reveals vasopressin V2-receptor-dependent signaling pathways in renal collecting duct cells. Proc Natl Acad Sci U S A 107, 3882-7 20139300 Curated Info
20	Choudhary C, et al. (2009) Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell 36, 326-39 19854140 Curated Info
21	Kim BG, et al. (2009) 'Two-stage double-technique hybrid (TSDTH)' identification strategy for the analysis of BMP2-induced transdifferentiation of premyoblast C2C12 cells to osteoblast. J Proteome Res 8, 4441-54 19655815 Curated Info
22	Zhou J (2009) CST Curation Set: 7431; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP Curated Info
23	Zhou J (2009) CST Curation Set: 7428; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP Curated Info
24	Zhou J (2009) CST Curation Set: 7429; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP Curated Info
25	Zhou J (2009) CST Curation Set: 7387; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: QXp[ST] Curated Info
26	Zhou J (2009) CST Curation Set: 7388; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: QXp[ST] Curated Info
27	Zhou J (2009) CST Curation Set: 7385; Year: 2009; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: QXp[ST] Curated Info
28	Zhou J (2009) CST Curation Set: 7386; Year: 2009; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: QXp[ST] Curated Info
29	Zhou J (2009) CST Curation Set: 7381; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: QXp[ST] Curated Info
30	Zhou J (2009) CST Curation Set: 7383; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: QXp[ST] Curated Info
31	Zhou J (2009) CST Curation Set: 7384; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: QXp[ST] Curated Info
32	Zhou J (2009) CST Curation Set: 7382; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: QXp[ST] Curated Info
33	Trost M, et al. (2009) The phagosomal proteome in interferon-gamma-activated macrophages. Immunity 30, 143-54 19144319 Curated Info
34	Zanivan S, et al. (2008) Solid tumor proteome and phosphoproteome analysis by high resolution mass spectrometry. J Proteome Res 7, 5314-26 19367708 Curated Info
35	Pan C, Gnad F, Olsen JV, Mann M (2008) Quantitative phosphoproteome analysis of a mouse liver cell line reveals specificity of phosphatase inhibitors. Proteomics 8, 4534-46 18846507 Curated Info
36	Trinidad JC, et al. (2008) Quantitative analysis of synaptic phosphorylation and protein expression. Mol Cell Proteomics 7, 684-96 18056256 Curated Info
37	Smith JC, et al. (2007) A differential phosphoproteomic analysis of retinoic acid-treated P19 cells. J Proteome Res 6, 3174-86 17622165 Curated Info
38	Guo A (2007) CST Curation Set: 2921; Year: 2007; Biosample/Treatment: tissue, liver/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](D/E)X(D/E) Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) CKII Substrate Antibody (polyAb) Cat#: 5808, PTMScan(R) Phospho-CK Substrate Motif (S/TD/EXD/E) Immunoaffinity Beads Cat#: 1994 Curated Info
39	Villén J, Beausoleil SA, Gerber SA, Gygi SP (2007) Large-scale phosphorylation analysis of mouse liver. Proc Natl Acad Sci U S A 104, 1488-93 17242355 Curated Info
40	Ballif BA, et al. (2004) Phosphoproteomic analysis of the developing mouse brain. Mol Cell Proteomics 3, 1093-101 15345747 Curated Info
41	Shu H, et al. (2004) Identification of phosphoproteins and their phosphorylation sites in the WEHI-231 B lymphoma cell line. Mol Cell Proteomics 3, 279-86 14729942 Curated Info